Literature DB >> 31520840

Diagnostic Cutoffs and Clinical Utility of Recombinant Aspergillus fumigatus Antigens in the Diagnosis of Allergic Bronchopulmonary Aspergillosis.

Valliappan Muthu1, Pawan Singh1, Hansraj Choudhary1, Inderpaul Singh Sehgal1, Sahajal Dhooria1, Kuruswamy Thurai Prasad1, Ashutosh Nath Aggarwal1, Mandeep Garg2, Arunaloke Chakrabarti3, Ritesh Agarwal4.   

Abstract

BACKGROUND: The clinical utility of IgE against recombinant Aspergillus fumigatus (rAsp)-specific antigens in allergic bronchopulmonary aspergillosis (ABPA) remains unclear.
OBJECTIVE: To identify the optimal diagnostic cutoffs of rAsp-specific IgE in differentiating ABPA from A fumigatus-sensitized asthma (ASA), and define their utility in the diagnosis of ABPA.
METHODS: We enrolled consecutive subjects with ASA and ABPA. IgE against rAsp f1, f2, f3, f4, and f6 was assayed in all the subjects. We evaluated 3 fixed cutoffs (0.35, 0.5, and 1.0 kUA/L) for their diagnostic performance in the entire cohort. We also divided the study population into derivation and validation cohorts. Cutoffs for rAsp-specific IgE were obtained using the receiver-operating characteristic analysis in the derivation cohort. We then evaluated the diagnostic performance of these cutoffs in the validation cohort. We further correlated rAsp-specific IgE levels in ABPA with asthma control, spirometry, imaging, and immunologic markers.
RESULTS: We included 194 subjects (123 ABPA and 71 ASA). The statistically derived cutoffs proved superior to fixed cutoffs. IgE against rAsp f1 yielded the best combination of sensitivity (89%) and specificity (100%). The sensitivity and specificity of IgE against either rAsp f1 (cutoff, 4.465 kUA/L) or f2 (cutoff, 1.300 kUA/L) for diagnosing ABPA were 100% and 81%, respectively. The correlation between rAsp-specific IgE and most clinical parameters of ABPA was weak.
CONCLUSIONS: IgE against rAsp f1 and f2 (using receiver-operating characteristic-derived cutoffs) were found to be the most useful in differentiating ABPA from ASA. Because this study was conducted at a single center, our results require further validation.
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABPA; Allergic bronchopulmonary mycosis; Allergy; Asthma; Fungal sensitization

Mesh:

Substances:

Year:  2019        PMID: 31520840     DOI: 10.1016/j.jaip.2019.08.041

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  5 in total

Review 1.  Allergic bronchopulmonary aspergillosis.

Authors:  Ritesh Agarwal; Inderpaul S Sehgal; Sahajal Dhooria; Valliappan Muthu; Kuruswamy T Prasad; Amanjit Bal; Ashutosh N Aggarwal; Arunaloke Chakrabarti
Journal:  Indian J Med Res       Date:  2020-06       Impact factor: 2.375

Review 2.  Aspergillus fumigatus-Host Interactions Mediating Airway Wall Remodelling in Asthma.

Authors:  Sara Namvar; Briony Labram; Jessica Rowley; Sarah Herrick
Journal:  J Fungi (Basel)       Date:  2022-02-06

3.  Basophil Activation Test With Aspergillus Molecules: The Case for ABPA.

Authors:  Moïse Michel; Youssouf Sereme; Farid Mankouri; Marion Gouitaa; Clarisse Gautier; Jean-Louis Mège; Carole Cassagne; Stéphane Ranque; Martine Reynaud-Gaubert; Joana Vitte
Journal:  Front Allergy       Date:  2022-06-22

4.  Allergic bronchopulmonary aspergillosis (ABPA) in an atopic patient with difficult-to-expectorate airway secretions.

Authors:  Marcus Joest
Journal:  Allergol Select       Date:  2021-05-27

Review 5.  Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis.

Authors:  Birce Sunman; Dilber Ademhan Tural; Beste Ozsezen; Nagehan Emiralioglu; Ebru Yalcin; Uğur Özçelik
Journal:  Front Pediatr       Date:  2020-10-20       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.